Table 2.
Initial medication after heart transplantation
| All | PVR < 300 | PVR ≥ 300 | Difference | 95% CI | P‐value | |
|---|---|---|---|---|---|---|
| dyn·s·cm−5 | dyn·s·cm−5 | |||||
| (<3.75 WU) | (≥3.75 WU) | |||||
| (n = 561) | (n = 467) | (n = 94) | ||||
| Cyclosporine A, n (%) | 337 (60.1%) | 281 (60.2%) | 56 (59.6%) | 0.6% | −10.3 to 11.5% | 0.91 |
| Tacrolimus, n (%) | 224 (39.9%) | 186 (39.8%) | 38 (40.4%) | 0.6% | −10.3 to 11.5% | 0.91 |
| Azathioprine, n (%) | 263 (46.9%) | 226 (48.4%) | 37 (39.4%) | 9.0% | −1.8 to 19.8% | 0.11 |
| Mycophenolate mofetil, n (%) | 298 (53.1%) | 241 (51.6%) | 57 (60.6%) | 9.0% | −1.8 to 19.8% | 0.11 |
| Steroids, n (%) | 561 (100.0%) | 467 (100.0%) | 94 (100.0%) | 0.0% | n.a. | n.a. |
| Acetylsalicylic acid (ASA), n (%) | 52 (9.3%) | 45 (9.6%) | 7 (7.4%) | 2.2% | −3.7 to 8.1% | 0.50 |
| Beta‐blocker, n (%) | 92 (16.4%) | 78 (16.7%) | 14 (14.9%) | 1.8% | −6.1 to 9.7% | 0.67 |
| Ivabradine, n (%) | 38 (6.8%) | 31 (6.6%) | 7 (7.4%) | 0.8% | −4.9 to 6.5% | 0.78 |
| Calcium channel blocker, n (%) | 140 (25.0%) | 117 (25.1%) | 23 (24.5%) | 0.6% | −8.9 to 10.1% | 0.90 |
| ACE inhibitor/sartan, n (%) | 248 (44.2%) | 214 (45.8%) | 34 (36.2%) | 9.6% | −1.1 to 20.3% | 0.09 |
| Diuretic, n (%) | 561 (100.0%) | 467 (100.0%) | 94 (100.0%) | 0.0% | n.a. | n.a. |
| Statin, n (%) | 215 (38.3%) | 177 (37.9%) | 38 (40.4%) | 2.5% | −8.3 to 13.3% | 0.65 |
| Gastric protection (PPI/H2 blocker), n (%) | 561 (100.0%) | 467 (100.0%) | 94 (100.0%) | 0.0% | n.a. | n.a. |
ACE, angiotensin‐converting enzyme; CI, confidence interval; dyn, g·cm·s−2; H2 blocker, histamine receptor blocker; n.a., not applicable; PPI, proton pump inhibitor; PVR, pulmonary vascular resistance; WU, Wood unit (≙ 80 dyn·s·cm−5).